Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics
15.5.2019 19:53:00 EEST | Business Wire | Press release
Scintomics GmbH and 1717 Life Science Ventures GmbH announced today to have signed an agreement to collaborate in the development of the theranostic pair PentixaFor / PentixaTher.
PentixaPharm GmbH, based in Würzburg, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.
Interviews: “We are delighted that in 1717 LSV we have found a strong partner with an outstanding expertise in the clinical development of precision oncologics. Taking the various recent and successful proof-of-concept studies with PentixaFor and PentixaTher in men into account, this joint venture creates optimal conditions for the effective and swift clinical development of this unrivalled and unique pair of theranostic drugs”, said Prof. Hans-Jürgen Wester, PhD, Founder of Scintomics and Chair for Pharmaceutical Radiochemistry at the Technical University of Munich (TUM), Germany.
“The introduction of 68 Ga-PentixaFor may be regarded as a milestone for clinical PET imaging of CXCR4 expressing malignancies”, added Dr. Hakim Bouterfa Co-founder of 1717 LSV GmbH and CEO of PentixaPharm. “Now we will focus on the next major step to provide CXCR4-directed endoradiotherapy in prospective clinical trials.”
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The Gallium-68 based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukaemia, lymphoma, and multiple myeloma – but also for other solid tumors like adrenocortical carcinoma, and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke and can be targeted with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalized cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics. Scintomics considers the joint venture partnership with 1717 LSV as another important milestone towards a strong positioning as radiopharmaceutical development specialist.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of targeted precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005776/en/
Contact information
For Scintomics
Saskia Kropf
General Manager
tel.
+49 8141 150 550
s.kropf@scintomics.com
www.scintomics.com
For
1717 LSV
Dr. Jens Kaufmann
General Manager
tel. +49
30 941084-422
jens.kaufmann@1717LSV.com
www.1717LSV.com
For
PentixaPharm
Dr. Hakim Bouterfa
CEO
tel. +49 172
6290822 or +49 931 304998310
hakim.bouterfa@1717LSV.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Albion and Tecnotree Partner to Deliver Next-Generation VAS Platform for TELUS in North America28.4.2026 10:00:00 EEST | Press release
Albion, a leading provider of telecom managed services and solutions, today announced that TELUS has selected Albion, in partnership with Tecnotree, to deliver a next-generation Value-Added Services (VAS) platform, with an initial deployment of a voicemail application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428959214/en/ Albion and Tecnotree Partner to Deliver Next-Generation VAS Platform for TELUS in North America Under the engagement, Albion will deliver the solution leveraging Tecnotree’s proven VAS and digital services platform, supporting TELUS’ objectives to modernize service capabilities; enhance the customer experience; and ensure scalable, future-ready service delivery. As part of the deployment, Albion will provide end-to-end managed services, including platform operations, service assurance, and ongoing lifecycle management, ensuring high availability and performance for TELUS customers across North Ame
Budweiser Partners with Football Icons Erling Haaland and Jürgen Klopp to Unleash New “Let it Pour” Platform for FIFA World Cup 2026 ™28.4.2026 10:00:00 EEST | Press release
Today, Budweiser, the Official Beer Sponsor of the FIFA World Cup 2026™, unveiled its newest global football platform, “Let It Pour,” cracking open four years' worth of anticipation for the game’s biggest stage. Activating across more than forty countries, the global beer icon is supercharging celebrations with Bud FC fan events, The Bud Fan Store, and a new global film calling the world together to Let It Pour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428722336/en/ Budweiser Partners with Football Icons Erling Haaland and Jürgen Klopp to Unleash New “Let it Pour” Platform for FIFA World Cup 2026™ “For over four decades, Budweiser has been part of the celebrations that define the FIFA World Cup™, be it on the pitch, in bars, or wherever fans come together,” said Richard Oppy, Global President, Premium Company at AB InBev. “‘Let It Pour’ is our invitation to consumers to fully embrace those moments. Alongside Erling
Roquette Showcases Its Expanded Consumer Healthcare Capabilities at Vitafoods Europe 202628.4.2026 10:00:00 EEST | Press release
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will present its expanded portfolio at Vitafoods Europe 2026 which is taking place from May 5 to May 7 in Barcelona. Roquette’s offering is designed to help consumer healthcare brands stay future‑ready and accelerate consumer-centric innovations for everyday well-being. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428405433/en/ Credits to Roquette As consumer expectations rise and shelf competition intensifies, dietary supplement and over-the-counter (OTC) brands, as well as contract development and manufacturing organizations (CDMOs), face growing pressure to deliver clean-label products that combine efficacy, strong sensory experiences, regulatory confidence, and speed to market. At Vitafoods Europe 2026, Roquette will demonstrate its role as a versatile partner, supporting customers from early concept to commercial launch a
LTM Launches BlueVerse™ Studio as a Hub for Enterprise Agentic AI Adoption28.4.2026 08:00:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of its BlueVerse Studio in Bengaluru, a hub designed to accelerate Enterprise Agentic AI adoption for clients and deliver measurable business outcomes. LTM continues to launch more studios globally to drive AI innovation and also has studios in London and Mumbai. As part of the company’s ongoing investment in bringing innovation closer to clients, the BlueVerse Studio was created to help clients scale AI solutions from experiments to practical applications while ensuring trust and control. It unites LTM’s strongest AI capabilities, including BlueVerse CraftStudio, physical AI showcases, and industry-centric AI offerings, within one ecosystem along with: Multiple BlueVerse-certified consulting and delivery professionals currently support enterprise-grade AI solutions. These certifications provide expertise in developing intelligent agents and managing unified AI platforms, ensuring secure
Microsoft and Postel: An Innovative New Data and AI-Driven Solution to Optimize Italian SMEs' Relationships with Their Customers28.4.2026 08:00:00 EEST | Press release
Microsoft and Postel, a Poste Italiane Group company, announce an evolution of their collaboration and of the agreements they have signed for the digitalization of Italian businesses, welcoming Audiencerate as technology partner in the Data and Direct & Digital Marketing space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427013396/en/ The Marketing Data Platform combines AI-powered market intelligence, first-party data and omnichannel activation to help SMEs analyze market trends and historical campaign performance, turning insights into audiences and increasingly targeted future actions. The agreement provides for the distribution of an integrated platform that combines Postel's omnichannel physical-and-digital communication capabilities with Audiencerate'sdata intelligence functionalities and Microsoft's AI and Cloud solutions. The solution enables SMEs to leverage and activate their own data across the entire custom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom